Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

about

Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome

P2860

Q37231446-2BFDB9DB-C0C1-4308-AFCC-E1469F42E9B3

P2860

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

Item

http://www.wikidata.org/entity/Q42731839

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

@en

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

@nl

type

Item

label

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

@en

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

@nl

prefLabel

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

@en

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

@nl

P1476

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

@en

P2093

George A Fisher

http://www.w3.org/2001/XMLSchema#string

Pamela L Kunz

http://www.w3.org/2001/XMLSchema#string

P2860

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours.

Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours.

Endocrine tumours of the gastrointestinal tract: Chemotherapy.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

P304

79-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEG.S5928

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21694850

http://www.w3.org/2001/XMLSchema#string

P932

3108662

http://www.w3.org/2001/XMLSchema#string

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

about

P2860

P2860

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932